Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.960
-0.080 (-3.92%)
Jul 13, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $334.03 million as of July 14, 2026. Its market cap has increased by 124.92% in one year.
Market Cap
334.03M
Enterprise Value
163.66M
1-Year Change
124.92%
Ranking
Category
Stock Price
$1.96
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $334.03M, an increase of 232.51%. That is a compound annual growth rate of 24.14%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 13, 2026 | 334.03M | 19.12% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vanda Pharmaceuticals | 375.25M |
| Vicore Pharma Holding AB | 372.65M |
| Fennec Pharmaceuticals | 364.39M |
| Fate Therapeutics | 361.33M |
| Lyell Immunopharma | 350.24M |
| Foghorn Therapeutics | 349.35M |
| Zentalis Pharmaceuticals | 347.39M |
| Palisade Bio | 340.22M |